Alteris Therapeutics, Inc.

Cancer vaccine targets variant EGF receptor

Published in Patient Care Law Weekly, March 21st, 2004

Alteris Therapeutics, Inc., announced that it has licensed additional rights to its lead therapeutic vaccine, ALT-110, from Duke University and Johns Hopkins University. ALT-110 is a therapeutic vaccine targeting EGFRvIII, a tumor-specific splice variant of the epidermal growth factor receptor (EGFR).

Both universities have taken an equity stake in Alteris as part of the licensing agreement. ALT-110 was originally identified by Albert Wong, MD, a founder of Alteris, while he was a researcher at Johns Hopkins. Alteris has previously licensed other technology rights relevant to ALT-110 from Thomas Jefferson University.

Splice variants result when...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Patient Care Law Weekly

Source: Patient Care Law Weekly (2004-03-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry